Neovasc (NVCN) Trading 5% Higher
Shares of Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) traded up 5% during trading on Wednesday . The stock traded as high as $0.64 and last traded at $0.63. 971,101 shares changed hands during trading, a decline of 16% from the average session volume of 1,152,250 shares. The stock had previously closed at $0.60.
Several analysts have recently commented on the company. ValuEngine upgraded Neovasc from a “hold” rating to a “buy” rating in a report on Wednesday, January 2nd. Zacks Investment Research upgraded Neovasc from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a report on Wednesday, November 21st.
The firm has a market cap of $14.84 million, a PE ratio of -0.02 and a beta of 1.59.
An institutional investor recently bought a new position in Neovasc stock. Capital Research Global Investors purchased a new position in shares of Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 704,769 shares of the medical equipment provider’s stock, valued at approximately $1,917,000. Capital Research Global Investors owned 3.62% of Neovasc as of its most recent filing with the SEC. 16.49% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2019/01/11/neovasc-nvcn-trading-5-higher.html.
Neovasc Company Profile (NASDAQ:NVCN)
Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.
Recommended Story: Earnings Per Share
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.